Multiomics and proteomic insights into Alzheimer’s disease biology in Down syndrome

Expert Review of Neurotherapeutics · Published 2026-06-25 · DOI 10.1080/14737175.2026.2695187

Free full text

Authors (2)

Mitchell Marta-Ariza, Thomas Wisniewski

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Marta-Ariza, M., Wisniewski, T. (2026). Multiomics and proteomic insights into Alzheimer’s disease biology in Down syndrome. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2026.2695187

Related articles

• Medication-overuse headache: can anti-CGRP monoclonal antibodies replace withdrawal? · Expert Review of Neurotherapeutics · 2025 · Same journal
• A conceptual framework based on current and emerging treatments for treatment-resistant depression: mechanistic evolution, clinical evidence, and future directions · Expert Review of Neurotherapeutics · 2026 · Same journal
• Optimizing cognitive behavioral therapy to treat anxiety among youth with autism spectrum disorders · Expert Review of Neurotherapeutics · 2025 · Same journal
• An update on the comorbidity of attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and its clinical management · Expert Review of Neurotherapeutics · 2025 · Same journal
• Building a new arsenal: repurposed drugs and metronomic chemotherapy against medulloblastoma · Expert Review of Neurotherapeutics · 2026 · Same journal
• Contemporary and evolving perspectives on surgical therapies for essential tremor: deep brain stimulation and focused ultrasound · Expert Review of Neurotherapeutics · 2026 · Same journal
• The latest views on how vagus nerve stimulation works in epilepsy: a plain language summary · Expert Review of Neurotherapeutics · 2025 · Same journal
• Advances in targeted closed loop spinal cord stimulation to treat pain of the trunk and limbs · Expert Review of Neurotherapeutics · 2026 · Same journal
• Speech and language outcome measures in clinical trials of Alzheimer’s and Parkinson’s diseases · Expert Review of Neurotherapeutics · 2025 · Same journal
• The path to clinical application of human microglia transplantation for the treatment of CSF1R-related disorder · Expert Review of Neurotherapeutics · 2026 · Same journal